Treatment of diabetic foot chronic ulcers and neuropathy with placenta-derived stem cells
Stem Cells Translational Medicine · 2026-10-16 · 15 (11)
DOI: 10.1093/stcltm/szag085 ↗Abstract
Abstract Aim This first in human study sought to determine the safety and clinical effects of placenta-derived stem cells (PSCs) administered by injection in a dose-escalation trial in diabetic subjects with foot ulceration (DFU) and peripheral neuropathy (DPN). Methods Subjects were enrolled with non-healing wounds of 10-100 cm2 despite standard therapy for ≥3 months. Objectives included safety, wound healing, changes in neuropathy and in ankle/foot vascular flow. Ten patients received PSC implantation to the DFU circumference, into the ulcer bed and along the pedal arteries, with a total dose escalation of 30, 40, and 60 million (M) cells in 4, 3, and 3 subjects, respectively. Results There were no PSC-treatment related serious adverse events. Wound healing was demonstrated in 10/10 subjects at 6 months. DPN improved in all subjects; with 9 of 10 achieving normal protective sensation by 12 months. Conclusions Local implantation of PSCs for DFU and DPN is safe and of potential clinical value.
EUVIMED